Skip to main content
Clinical Trials/CTRI/2021/09/036489
CTRI/2021/09/036489
Completed
未知

Development, validation, pilot deployment of an ultra scalable technology SWAASA AI, as an auxiliary to COVID 19 rapid test.

Cellular and Molecular Platforms0 sites656 target enrollmentTBD

Overview

Phase
未知
Intervention
Not specified
Conditions
Health Condition 1: B972- Coronavirus as the cause of diseases classified elsewhere
Sponsor
Cellular and Molecular Platforms
Enrollment
656
Status
Completed
Last Updated
3 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
February 17, 2022
Last Updated
3 years ago
Study Type
Observational

Investigators

Sponsor
Cellular and Molecular Platforms

Eligibility Criteria

Inclusion Criteria

  • Male or female patients, 18 years of age and over.
  • Patients able to read, understand and sign the Informed Consent Form.
  • Newly diagnosed COVID 19 Patients.

Exclusion Criteria

  • Patients less than 18 years of age
  • Pregnant females.
  • Asymptomatic patients attending isolation ward for COVID testing
  • Patients on ventilators support

Outcomes

Primary Outcomes

Not specified

Similar Trials